Want to see IN:ROSSARI full AI Analyst Report?
Top Page
Rossari Biotech Ltd
(ROSSARI)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹442.00
▼(-24.31% Downside)
Action:Reiterated
Date:08/09/26
The score is held back primarily by weak cash generation (volatile operating cash flow and persistently negative, deeply negative 2026 free cash flow) and some 2026 margin pressure, despite steady revenue growth and an otherwise reasonably healthy balance sheet. Technicals are mixed with slightly negative momentum, while valuation is moderate but not strongly supported by the very low dividend yield.
Positive Factors
Steady revenue expansion
Sustained revenue expansion indicates Rossari has continued broadening demand for its specialty chemical offerings across its served markets. Although growth cooled in 2026, the multi-year trajectory supports ongoing customer adoption and provides a foundation for future operating scale.
Negative Factors
Weak cash conversion
Weak conversion of reported earnings into operating cash reduces Rossari’s ability to fund expansion internally and increases reliance on external financing. Persistently negative free cash flow may reflect heavy investment or working-capital needs, limiting flexibility during weaker demand or cost conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue expansion
Sustained revenue expansion indicates Rossari has continued broadening demand for its specialty chemical offerings across its served markets. Although growth cooled in 2026, the multi-year trajectory supports ongoing customer adoption and provides a foundation for future operating scale.
Read all positive factors
Rossari Biotech Ltd (ROSSARI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹23.66B
Dividend Yield0.12%
Average Volume (3M)3.81K
Price to Earnings (P/E)15.5
Beta (1Y)1.14
Revenue Growth19.47%
EPS Growth11.49%
CountryIN
Employees585
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)27.22
Shares Outstanding55,394,115
10 Day Avg. Volume3,692
30 Day Avg. Volume3,807
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)1.57
Price to Sales (P/S)0.87
P/FCF Ratio-9.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.2
Revenue Forecast (FY)₹26.52B
Rossari Biotech Ltd Business Overview & Revenue Model
Company Description
Rossari Biotech Limited, an India-based company, is a global manufacturer and distributor of specialized chemical products. Its diverse offerings cater to numerous industries, including ingredients for soaps and detergents, formulations for inks, ...
How the Company Makes Money
Rossari Biotech makes money primarily by selling specialty chemical formulations and allied solutions to business customers (B2B). Its revenue model is driven by: (1) Product sales across application categories: The company supplies textile specia...
Rossari Biotech Ltd Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.50B | 23.96B | 20.80B | 18.31B | 16.56B | 14.83B |
| Gross Profit | 5.83B | 4.94B | 6.47B | 5.26B | 2.80B | 2.29B |
| EBITDA | 3.24B | 2.86B | 2.65B | 2.57B | 2.12B | 1.94B |
| Net Income | 1.51B | 1.49B | 1.36B | 1.31B | 1.07B | 976.74M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 22.89B | 18.96B | 15.72B | 13.68B | 12.57B |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 1.27B | 1.14B | 667.85M | 1.52B | 644.26M |
| Total Debt | 0.00 | 4.36B | 2.18B | 1.19B | 739.28M | 84.27M |
| Total Liabilities | -13.33B | 9.55B | 7.11B | 5.24B | 4.52B | 4.52B |
| Stockholders Equity | 13.33B | 13.33B | 11.85B | 10.48B | 9.15B | 8.05B |
Cash Flow | ||||||
| Free Cash Flow | -1.67B | -2.20B | -210.69M | -880.28M | 1.20B | -88.67M |
| Operating Cash Flow | -250.32M | 451.63M | 1.37B | 432.55M | 1.52B | 293.58M |
| Investing Cash Flow | -1.06B | -2.22B | -1.84B | -1.03B | -1.81B | -2.99B |
| Financing Cash Flow | 1.22B | 2.09B | 649.01M | 161.85M | 608.55M | 2.92B |
Rossari Biotech Ltd Technical Analysis
Negative
583.95
Price Trends
474.37
Negative
497.82
Negative
502.02
Negative
Market Momentum
-13.92
Negative
32.60
Neutral
26.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Negative. The current price of 583.95 is above the 20-day moving average (MA) of 439.01, above the 50-day MA of 474.37, and above the 200-day MA of 502.02, indicating a bearish trend. The MACD of -13.92 indicates Negative momentum. The RSI at 32.60 is Neutral, neither overbought nor oversold. The STOCH value of 26.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ROSSARI.
Rossari Biotech Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹68.93B | 48.17 | ― | 0.22% | 91.44% | 19.67% | |
68 Neutral | ₹86.56B | 24.39 | ― | 0.90% | 27.05% | 16.13% | |
62 Neutral | ₹36.80B | 0.58 | ― | 0.10% | 10.71% | 2756.39% | |
57 Neutral | ₹23.66B | 15.54 | ― | 0.12% | 19.47% | 11.49% | |
56 Neutral | ₹74.14B | 34.07 | ― | 0.51% | 11.08% | 34.10% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹44.07B | 90.63 | ― | 0.10% | 41.09% | 618.16% |
* General Sector Average
IN:ROSSARI
Rossari Biotech Ltd
422.00
-242.66
-36.51%
IN:BALAMINES
Balaji Amines Limited
2,158.85
786.60
57.32%
IN:FCL
Fineotex Chemical Limited
57.85
33.54
137.98%
IN:GALAXYSURF
Galaxy Surfactants Ltd.
2,434.15
207.54
9.32%
IN:KIRIINDUS
Kiri Industries Limited
556.25
-35.10
-5.94%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,994.50
935.12
88.27%
Rossari Biotech Ltd Corporate Events
Rossari Biotech Sets July 20 Investor Call on Q1 FY27 Results
Jul 14, 2026
Rossari Biotech Ltd has scheduled an earnings conference call for investors and analysts to discuss its financial performance for the first quarter of fiscal year 2027. The call, to be held on Monday, July 20, 2026 at 5:00 p.m. IST, will include a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.